Veliparib + Cisplatin + Vinorelbine
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation
Conditions
Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer
Trial Timeline
— → —
NCT ID
NCT02985658About Veliparib + Cisplatin + Vinorelbine
Veliparib + Cisplatin + Vinorelbine is a pre-clinical stage product being developed by AbbVie for Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation. The current trial status is completed. This product is registered under clinical trial identifier NCT02985658. Target conditions include Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02985658 | Pre-clinical | Completed |
Competing Products
20 competing products in Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation